AI Article Synopsis
- Kinase inhibitors approved for cancer treatment might also be effective for autoimmune diseases due to off-target effects.
- Case reports suggest that drugs like erlotinib and gefitinib have potential in treating conditions such as psoriasis, inflammatory bowel disease, and rheumatoid arthritis.
- This indicates a broader applicability of these medications beyond just cancer therapy.
Article Abstract
Kinase inhibitors that enter clinical use as treatments for cancer may have off-target effects, making them efficacious in the treatment of autoimmune diseases. Case reports are presented on the potential of erlotinib and gefitinib for treating psoriasis, inflammatory bowel disease, rheumatoid arthritis, and other nonautoimmune inflammatory disorders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556266 | PMC |
| http://dx.doi.org/10.1634/theoncologist.2012-0219 | DOI Listing |
Publication Analysis
Top Keywords
erlotinib gefitinib
8
kinase inhibitors
8
gefitinib epidermal
4
epidermal growth
4
growth factor
4
factor receptor
4
receptor kinase
4
inhibitors treat
4
treat non-cancer-related
4
non-cancer-related tumor
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!